NICODERM CQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NICODERM CQ (NICODERM CQ).
Nicotine is a nicotinic cholinergic receptor agonist that stimulates ganglia and the CNS, leading to release of catecholamines and other neurotransmitters. In smoking cessation, it acts as a replacement therapy to reduce withdrawal symptoms and cravings by binding to nicotinic acetylcholine receptors in the brain.
| Metabolism | Primarily hepatic metabolism via CYP2A6 (major) and CYP2B6 (minor) to cotinine, which is further metabolized to trans-3'-hydroxycotinine. Also undergoes N-glucuronidation and renal excretion. |
| Excretion | Primarily renal; about 10-20% excreted unchanged, remainder as metabolites (cotinine and nicotine-N'-oxide). Total clearance ~1.2 L/min. Biliary/fecal excretion negligible (<5%). |
| Half-life | Terminal elimination half-life ~2 hours (range 1-4 h) after transdermal patch removal; clinically, levels decline rapidly, requiring scheduled reapplication. |
| Protein binding | <5%; primarily binds to albumin (4.9%) and α1-acid glycoprotein; binding is minimal and not clinically relevant. |
| Volume of Distribution | 2-3 L/kg (mean 2.6 L/kg); indicates extensive distribution into tissues including brain, liver, kidneys, and skeletal muscle. |
| Bioavailability | Transdermal: ~82% (range 68-92%) of dose delivered systemically; oral bioavailability is <30% due to first-pass metabolism; intranasal: 50-80%; nicotine gum: 50-80% depending on buccal absorption. |
| Onset of Action | Transdermal: steady-state plasma concentrations achieved after 2-4 hours of patch application; clinical effects (craving reduction) detectable within 30-60 minutes. |
| Duration of Action | Patches designed for 24-hour wear; therapeutic nicotine levels maintained for 24 hours after application; after removal, levels decline with t1/2 of 2 h, effects wane over 4-8 hours. |
Apply one 7 mg/24 hour, 14 mg/24 hour, or 21 mg/24 hour transdermal patch to non-hairy, clean, dry skin on the upper body or upper outer arm once daily. Initial dose based on smoking status: patients smoking >10 cigarettes/day: 21 mg/24 hours; patients smoking ≤10 cigarettes/day: 14 mg/24 hours. Titrate based on withdrawal symptoms.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | Severe renal impairment (GFR <30 mL/min): use with caution; dose reduction may be necessary due to decreased clearance of nicotine and its metabolites. No specific dosing guidelines available; monitor for adverse effects. |
| Liver impairment | Child-Pugh Class A: no adjustment. Class B: reduce starting dose by 50% (e.g., start with 7 mg/24 hours). Class C: avoid use due to risk of accumulation; if used, dose reduction and careful monitoring required. |
| Pediatric use | Not recommended for patients under 18 years of age. Safety and efficacy not established. Avoid use in children and adolescents. |
| Geriatric use | Elderly patients may have decreased renal function; start with lower dose (e.g., 7 mg or 14 mg/24 hours) and titrate slowly. Monitor for adverse effects such as dizziness and hypotension. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NICODERM CQ (NICODERM CQ).
| Breastfeeding | Nicotine is excreted into breast milk (M/P ratio approximately 2.9). Infant exposure via milk can cause adverse effects (e.g., vomiting, diarrhea, tachycardia). Avoid NRT during breastfeeding unless benefits outweigh risks; if used, minimize infant exposure by timing dose after feeding and using intermittent rather than continuous delivery. |
| Teratogenic Risk | Nicotine is a known teratogen. First trimester: increased risk of spontaneous abortion and congenital anomalies (e.g., oral clefts, limb defects). Second/third trimesters: risk of fetal growth restriction, preterm birth, stillbirth, and placental abruption. Risk is dose-dependent; NRT may reduce risks compared to smoking but is not risk-free. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to nicotine or any component of the patch","Pregnancy and breastfeeding (nicotine replacement is generally contraindicated, but may be used under medical supervision if benefits outweigh risks)","Recent myocardial infarction (within 2 weeks)","Serious cardiac arrhythmias","Unstable angina pectoris"]
| Precautions | ["Risk of nicotine toxicity in overdose","Use with caution in patients with cardiovascular disease (e.g., recent MI, serious arrhythmias)","May cause fetal harm; contraindicated in pregnancy (Pregnancy Category D)","Skin reactions at application site","Nicotine withdrawal symptoms may occur upon abrupt discontinuation"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and nicotine withdrawal symptoms. Fetal monitoring: serial ultrasound for growth and amniotic fluid index, nonstress test or biophysical profile in third trimester if continued use. Assess for signs of preterm labor or abruption. |
| Fertility Effects | Female: nicotine may impair fallopian tube function, reduce ovarian reserve, and increase time to conception. Male: nicotine can reduce sperm count, motility, and increase DNA fragmentation. Effects are partially reversible upon cessation. |